OmniAb to Report Second Quarter 2024 Financial Results on August 8
OmniAb, Inc. (NASDAQ: OABI) has announced that it will release its financial results for the second quarter of 2024 on Thursday, August 8, 2024, after the U.S. financial markets close. The company will also host a conference call and webcast on the same day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss the results and provide business updates. Interested parties can access the call using the provided U.S. and international phone numbers, with the conference ID 01718. A live webcast and replay of the call, along with accompanying slides, will be available on the company's website.
OmniAb, Inc. (NASDAQ: OABI) ha annunciato che rilascerà i suoi risultati finanziari per il secondo trimestre del 2024 giovedì 8 agosto 2024, dopo la chiusura dei mercati finanziari americani. L'azienda organizzerà anche una chiamata conferenza e un webcast lo stesso giorno alle 16:30 ora orientale (13:30 ora del Pacifico) per discutere i risultati e fornire aggiornamenti sull'attività. Le parti interessate possono partecipare alla chiamata utilizzando i numeri di telefono forniti per gli Stati Uniti e internazionali, con ID conferenza 01718. Un webcast in diretta e la registrazione della chiamata, insieme alle diapositive associate, saranno disponibili sul sito web dell'azienda.
OmniAb, Inc. (NASDAQ: OABI) ha anunciado que publicará sus resultados financieros para el segundo trimestre de 2024 el jueves 8 de agosto de 2024, después del cierre de los mercados financieros en EE. UU. La empresa también llevará a cabo una llamada de conferencia y webcast el mismo día a las 4:30 p.m. hora del este (1:30 p.m. hora del Pacífico) para discutir los resultados y proporcionar actualizaciones comerciales. Las partes interesadas pueden acceder a la llamada utilizando los números de teléfono proporcionados para EE. UU. e internacionales, con la ID de conferencia 01718. Un webcast en vivo y la repetición de la llamada, junto con las diapositivas correspondientes, estarán disponibles en el sitio web de la empresa.
OmniAb, Inc. (NASDAQ: OABI)가 2024년 2분기 재무 결과를 2024년 8월 8일 목요일에 미국 금융 시장이 마감된 후 발표하겠다고 발표했습니다. 회사는 같은 날 동부 표준시 오후 4시 30분 (태평양 표준시 오후 1시 30분)에 컨퍼런스 콜과 웹캐스트를 진행하여 결과를 논의하고 사업 업데이트를 제공할 예정입니다. 관심 있는 분들은 제공된 미국 및 국제 전화번호를 사용하여 콜에 접속할 수 있으며, 컨퍼런스 ID는 01718입니다. 생방송 웹캐스트와 콜의 재생, 함께하는 슬라이드는 회사의 웹사이트에서 확인할 수 있습니다.
OmniAb, Inc. (NASDAQ: OABI) a annoncé qu'elle publiera ses résultats financiers pour le deuxième trimestre de 2024 le jeudi 8 août 2024, après la fermeture des marchés financiers américains. L'entreprise organisera également une conférence téléphonique et un webcast le même jour à 16h30, heure de l'Est (13h30, heure du Pacifique) pour discuter des résultats et fournir des mises à jour commerciales. Les parties intéressées peuvent accéder à l'appel en utilisant les numéros de téléphone fournis pour les États-Unis et à l'international, avec l'ID de conférence 01718. Un webcast en direct et un replay de l'appel, ainsi que les diapositives associées, seront disponibles sur le site web de l'entreprise.
OmniAb, Inc. (NASDAQ: OABI) hat angekündigt, dass es seine finanziellen Ergebnisse für das zweite Quartal 2024 am Donnerstag, den 8. August 2024 nach dem Handelsschluss der US-Finanzmärkte veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time (13:30 Uhr Pacific Time) eine Konferenzschaltung und ein Webcast veranstalten, um die Ergebnisse zu besprechen und Geschäftsinformationen zu geben. Interessierte Parteien können unter den bereitgestellten US- und internationalen Telefonnummern mit der Konferenz-ID 01718 an der Schaltung teilnehmen. Ein Live-Webcast und eine Wiederholung der Schaltung sowie die begleitenden Folien werden auf der Website des Unternehmens verfügbar sein.
- None.
- None.
Conference Call and Webcast Information
What: |
|
OmniAb conference call to discuss financial results and business updates |
|
|
|
Date: |
|
Thursday, August 8, 2024 |
|
|
|
Time: |
|
4:30 p.m. Eastern time (1:30 p.m. Pacific time) |
|
|
|
Conference Call: |
|
|
|
|
International (289) 819 1520 |
|
|
Conference ID is 01718 |
|
|
|
Webcast: |
|
Live and replay webcast of the call with slides will be available here. |
About OmniAb®
OmniAb licenses cutting edge discovery research technology to the pharmaceutical and biotech industry to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is something we call Biological Intelligence™ (BI), which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, are used to identify fully-human antibodies with exceptional performance and developability characteristics.
Our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® have been genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic® and OmniClic® are fixed or common light-chain rats and chickens, respectively, designed to facilitate the discovery of bispecific antibodies. OmniTaur™ provides cow-inspired antibodies with unique structural characteristics for challenging targets. OmnidAb™, is an in vivo platform for the discovery of single domain antibodies based upon a human VH scaffold that affinity matures in a chicken host environment to provide a functionally diverse immune repertoire unavailable from mammalian systems. Our proprietary technologies are joined with and leverage OmniDeep™, which is a suite of in silico, AI and machine learning tools for therapeutic discovery and optimization that are woven throughout our various technologies and capabilities. Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb’s technology and creates opportunities in many important and emerging target classes.
OmniAb technologies can be leveraged for the discovery of a variety of next-generation antibody-based therapeutic modalities, including bi- and multi-specific biologics, antibody-drug conjugates, CAR-T therapies, targeted radiotherapeutics, and many others.
For more information, please visit www.omniab.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240725888853/en/
OmniAb, Inc.
Kurt Gustafson
investors@OmniAb.com
X (Twitter) @OmniAbTech
(510) 768-7760
Source: OmniAb, Inc.
FAQ
When will OmniAb (OABI) report its Q2 2024 financial results?
What time is OmniAb's (OABI) Q2 2024 earnings conference call?
How can I access OmniAb's (OABI) Q2 2024 earnings call?
Will OmniAb (OABI) provide a webcast of its Q2 2024 earnings call?
